Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q969F8

UPID:
KISSR_HUMAN

ALTERNATIVE NAMES:
G-protein coupled receptor 54; G-protein coupled receptor OT7T175; Hypogonadotropin-1; Kisspeptins receptor; Metastin receptor

ALTERNATIVE UPACC:
Q969F8; A5D8U2; B2RTV1; Q96QG0

BACKGROUND:
KiSS-1 receptor, identified for its metastasis suppressor properties in melanomas and breast carcinomas, is a key player in puberty and reproductive system regulation. It binds to kisspeptin-54, facilitating normal puberty onset and gonadotropin-releasing hormone regulation. Its role extends to trophoblast invasion regulation, highlighting its importance in reproductive health.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of KiSS-1 receptor could open doors to potential therapeutic strategies for addressing reproductive disorders such as Hypogonadotropic hypogonadism and Precocious puberty, by modulating its pathway.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.